HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Robbins, R. C. Articles by Oyer, P. E. Search for Related Content PubMed PubMed Citation Articles by Robbins, R. C. Articles by Oyer, P. E. Related Collections Mechanical Circulatory Assistance

Ann Thorac Surg 2001;71:S162-S165
© 2001 The Society of Thoracic Surgeons

---

Session 4: pulsatile implantable devices

The totally implantable Novacor Left Ventricular Assist System

^a Department of Cardiothoracic Surgery, Stanford University School of Medicine, Stanford, California, USA

Address reprint requests to Dr Robbins, Department of Cardiothoracic Surgery, Falk Cardiovascular Research Center, Stanford University School of Medicine, Stanford, CA 94305-5407
e-mail: robbins{at}leland.stanford.edu

Presented at the Fifth International Conference on Circulatory Support Devices for Severe Cardiac Failure, New York, NY, Sept 15–17, 2000.

Abstract

The Novacor Left Ventricular Assist System (LVAS) (Novacor Corp, Oakland, CA) was initially console-based and has been available since 1993 in a wearable configuration. It has been successfully used for the past 16 years as a bridge to cardiac transplantation in patients with end-stage congestive heart failure. The Stanford experience represents 53 patients (48 male, 5 female) with a mean age of 44 ± 13 years (16 to 62) and a mean support time of 56 ± 76 days (1 to 374). Complications with LVAS use consisted predominantly of bleeding (43%), infection, (30%), and embolic cerebrovascular events (24.5%). Sixty-six percent of the supported patients were successfully bridged to cardiac transplantation. In animal studies, 4 sheep had the totally implantable configuration in place for a cumulative duration of 1 year with 1 animal supported for 260 days. The next generation Novacor LVAS will be small, quiet, and fully implantable without the need for volume compensation. It will also provide physiologic pulsatile flow and will be fail-safe.

This article has been cited by other articles:

				M. E. Stone Current Status of Mechanical Circulatory Assistance Seminars in Cardiothoracic and Vascular Anesthesia, September 1, 2007; 11(3): 185 - 204. [Abstract] [PDF]

				N. C. Dang, V. K. Topkara, B. T. Kim, M. L. Mercando, J. Kay, and Y. Naka Clinical outcomes in patients with chronic congestive heart failure who undergo left ventricular assist device implantation J. Thorac. Cardiovasc. Surg., November 1, 2005; 130(5): 1302 - 1309. [Abstract] [Full Text] [PDF]

				N. C. Dang, V. K. Topkara, M. Leacche, R. John, J. G. Byrne, and Y. Naka Left ventricular assist device implantation after acute anterior wall myocardial infarction and cardiogenic shock: A two-center study J. Thorac. Cardiovasc. Surg., September 1, 2005; 130(3): 693 - 698. [Abstract] [Full Text] [PDF]

				M. Haddad, R. G. Masters, P. J. Hendry, A. Kawai, J. P. Veinot, G. Lavallee, and T. V. Mussivand Intercontinental LVAS Patient Transport Ann. Thorac. Surg., November 1, 2004; 78(5): 1818 - 1820. [Abstract] [Full Text] [PDF]

				E. L. Kukuy, M. C. Oz, and Y. Naka Long-Term Mechanical Circulatory Support Card. Surg. Adult, January 1, 2003; 2(2003): 1491 - 1506. [Full Text]

				W. L. Holman, J. E. Davies, B. K. Rayburn, D. C. McGiffin, B. A. Foley, R. L. Benza, R. C. Bourge, P. Blood, and J. K. Kirklin Treatment of end-stage heart disease with outpatient ventricular assist devices Ann. Thorac. Surg., May 1, 2002; 73(5): 1489 - 1494. [Abstract] [Full Text] [PDF]